

Board of Directors

Almirall

Mr. Carlos Gallardo Piqué

Professional profile and biography

Carlos Gallardo joined the pharmaceutical industry over 20 years ago when he joined Pfizer based in New York.

In 2004, he joined Almirall where he has remained until the present day. First as an executive in different countries and positions ranging from Strategy, Sales, Licensing, M&A and to Country Management. In 2013, he was appointed Board Director. He became Vice Chairman in 2020 and Chairman as of May 2022. In November 2022, he was appointed interim CEO and in light of the very positive evolution and performance, in February 2023 he was appointed CEO.

Additionally, Carlos has established a successful career in innovative healthcare technology. He is the founder of CG Health Ventures, which invests in early-stage digital health and medtech companies globally, providing a unique blend of operational support and capital.

Before joining the pharmaceutical industry, Carlos worked as an engineer in the automotive industry in logistics and supply chain. He holds a MS in industrial engineering from the Universitat Politècnica de Catalunya and an MBA from Stanford Graduate School of Business.

Other significant Boards to which he belongs, listed companies or otherwise

Olistic.

Member category

Executive Director.

Date of first appointment, and subsequent appointments

First appointment 25/07/2014 by co-option; re-elected on 07/11/2014, on 08/05/2019, on 07/05/21 and on 05/05/2023.

Company shares, and share options

Direct holder of 1,072 shares and indirect holder, together with other family members through the company Grupo Plafin, S.A., of 93,169,300 company shares, and indirect holder, together with other family members through Grupo Corporativo Landon, S.L., of 32,766,155 company shares.

Sir Tom McKillop

Professional profile and biography

Sir Tom McKillop began his career at ICI where he held various positions before being appointed Technical Director. In 1992 he was appointed deputy CEO and in 1994 he became CEO of Zeneca Pharmaceuticals, leading the merger of Astra and Zeneca in 1999, and becoming CEO of AstraZeneca plc until retiring at the end of 2005. Until 2009, he was the Chairman of the Royal Bank of Scotland and a Non-Executive Director of BP. He has been Chairman or non-executive director of various other healthcare companies and received numerous academic awards and honorary degrees.

Other significant Boards to which he belongs, listed companies or otherwise

None.

Member category

External Director.

Date of first appointment, and subsequent appointments

First appointment on 29/05/2007. Re-elected on 04/05/2012, on 09/05/2018, on 08/05/2019 and on 05/05/2023.

Company shares, and share options

None.

Dr. Karin Louise Dorrepaal

Professional profile and biography

Dr. Dorrepaal has a PhD from the Free University of Amsterdam, following four years as a research fellow in the Netherlands Cancer Institute. She also holds an MBA from the Rotterdam School of Management. In 1990, she joined Booz Allen Hamilton, Management Consultants, where she remained until 2004, being appointed Vice President in 2000. She specializes in the pharmaceutical industry and has advised large companies on strategy, sales, marketing, and supply chain issues. In 2004, she was appointed to the Board of Executive Directors of ScheringAG. Following the acquisition of this company by Bayer AG, Dr. Dorrepaal left her position. Currently she is on the Board of Directors of Gerresheimer AG, Paion AG, the Kerry Group Plc., and is on the Industry Board of Triton Private Equity (in Germany), as well as some family owned companies and non-quoted companies.

Other significant Boards to which she belongs, listed companies or otherwise

Gerresheimer AG, Paion AG and The Kerry Group plc.

Member category

Independent Director.

Date of first appointment as company board member, and subsequent appointment

First appointment on 16/11/2012 by co-option, effective as of 01/01/2013. Re-elected on 08/05/2019 and on 05/05/2023.

Company shares, and share options

None.

Dr. Seth J. Orlow

Professional profile and biography

Dr. Orlow holds a Doctor of Medicine and a PhD in Molecular Pharmacology from the Albert Einstein College of Medicine (US) and a Bachelor of Arts in Biochemical Science from Harvard University (US). He serves as a Senior Advisor to Pharus Advisors, a merchant bank. In the past, Dr. Orlow was, among other roles, a partner at Easton Capital Partners, a venture capital firm, a co-founder of Anadern Research Corporation (acquired by Pfizer), and a director of Protez Pharmaceuticals and Transave, Inc. Throughout his career, Dr. Orlow has been a Professor in the Departments of Dermatology, Cell Biology, and Pediatrics at the NYU Grossman School of Medicine, where he has also served as Chair of the Ronald O. Perelman Department of Dermatology since 2006.

Other significant Boards to which he belongs, listed companies or otherwise

R2 Technologies, Inc.

Member category

Independent Director.

Date of first appointment, and subsequent appointments

First appointment on 06/05/2016; re-elected on 23/07/2020, on 07/05/2021, on 05/05/2022 and on 05/05/2023.

Company shares, and share options

None.

Mr. Enrique de Leyva Pérez

Professional profile and biography

Mr. de Leyva holds an M.Sc. Degree in Civil Engineering from the Polytechnic University of Madrid and an MBA from Columbia Business School, where he was a Fulbright Scholar and specialized in Finance and Accounting. He has developed his career in top-level companies such as Unión Fenosa (1983-1986), and McKinsey & Company (1986-2006), in various executive positions and countries (including the UK and US), and is -since 2006-, one of the founding partners of Magnum Industrial Partners, a leading Iberian private equity firm which has launched three funds to the market with c. €1.5 billion of committed capital. He also belongs to the Boards of Directors of Ontime, Universal Diagnostics as well as several portfolio companies of the Magnum Funds. He has been Chairman or Director of companies in the Education, Energy, Industry, Agriculture, Health Care, B2B Services and Telecommunications industries.

Other significant Boards to which he belongs, listed companies or otherwise

Ontime, Universal Diagnostics.

Member category

Independent Director.

Date of first appointment, and subsequent appointments

First appointment on 22/02/2019 by co-option; re-elected on 08/05/2019, on 07/05/2021 and on 05/05/2023.

Company shares, and share options

17,980 shares.

Dr. Alexandra B. Kimball

Professional profile and biography

Dr. Alexandra B. Kimball holds an AB in Molecular Biology from Princeton University, an MD from Yale University School of Medicine, and an MPH from Johns Hopkins School of Public Health. Professor Kimball is the President and CEO of Harvard Medical Faculty Physicians (HMFP) at Beth Israel Deaconess Medical Centre (BIDMC), member of the BIDMC Board of Directors and a dermatologist at the same centre. She is a Professor of Dermatology at the Harvard Medical School, as well as the Co-Chair of the Management Board at Beth Israel Lahey Health Performance Network (BILPN). In recognition of her research on physician workforce economics, quality of life, and outcomes, she was awarded the American Skin Association Research Award for Health Policy and Medical Education and the Mass General Hospital Bowditch Prize. Other awards include Mentor of the Year from the Women's Derm Society and the Outstanding Physician-Clinician and Lifetime Achievement Awards from the National Psoriasis Foundation. Dr. Kimball has served on the non-profit Boards of the Society for Investigative Dermatology, the Massachusetts Foundation for the Humanities and Public Policy, and the Hidradenitis Suppurativa Foundation. She is past President of the International Psoriasis Council and serves on the Advisory Committee to the Director of the National Institutes of Health.

Other significant Boards to which she belongs, listed companies or otherwise

Beth Israel Lahey Health, Beth Israel Deaconess Medical Center, Physicians LLC. and American Dermatologic Association.

Member category

Independent Director.

Date of first appointment, and subsequent appointments

First appointment on 24/07/2020; re-elected on 07/05/2021 and on 05/05/2023.

Company shares, and share options

None.

Ms. Eva-Lotta Allan

Professional profile and biography

Ms. Eva-Lotta Allan holds a degree in Natural Sciences from Jakobsbergskolan (Stockholm) and Microbiology from the Laboratory School University (Stockholm), and a Master Certificate in Marketing from the Institute for Higher Marketing Business School (Stockholm). Ms. Allan is Chairperson of the Board and member of the Audit and Remuneration Committee at Draupnir Bio, Chairperson of the Board of Naxon, and Non-Executive Director of Aleta Biotherapeutics and Crescendo Biologics.

Other significant Boards to which she belongs, listed companies or otherwise

Aleta Biotherapeutics, Crescendo Biologics, Draupnir Bio and Maxion.

Member category

Independent Director.

Date of first appointment, and subsequent appointments

First appointment on 21/07/2020; re-elected on 07/05/2021 and on 05/05/2023.

Company shares, and share options

None.

Dr. Ruud Dobber

Professional profile and biography

Master of Science (University of Utrecht, The Netherlands) and PhD in Immunology (University of Leiden, The Netherlands). Dr. Dobber was appointed in January 2019 Executive Vice-President, BioPharmaceuticals Business in AstraZeneca and is responsible for product strategy and commercial delivery for Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology and Vaccines & Immune therapies. Prior to this, Dr. Dobber held several executive roles at AstraZeneca, among others President at AstraZeneca US and Executive Vice-President North America, Executive Vice-President Europe, Regional Vice-President Europe, Middle East and Africa, Regional Vice-President Asia Pacific or Area Vice-President Europe 1. In addition, Dr. Dobber was a member of the Board and Executive Committee of EFPIA and Chairman of the Asia division of Pharmaceutical Research and Manufacturers of America.

Other significant Boards to which he belongs, listed companies or otherwise

None.

Member category

Independent Director.

Date of first appointment as company board member, and subsequent appointments

First appointment on 18/06/2021, by the Shareholders Meeting, and re-elected on 05/05/2023.

Company shares, and share options

None.

Mr. Antonio Gallardo Torrededía

Professional profile and biography

Mr. Antonio Gallardo holds a degree in Business Science from the University of Barcelona and an Executive MBA from the University of Chicago. He also has a Master's degree in Marketing from ESADE. He developed his professional career over seven years at Akzo Nobel, reaching the role of Marketing Director. In 1999 he joined Almirall as Area Manager. Later, he was Director of Pharmacy Marketing and developed a loyalty programme consisting of 10,000 pharmacies through the network of medical representatives in Spain, after which he joined the medical visit network as Area Manager and later as Division Chief. In 2008, he left Almirall to continue in the family business, where he took charge of the real estate area, as the Chairman of The Landon Group.

Other significant Boards to which he belongs, listed companies or otherwise

Acornseekers, Goodnews and Newwork co-working.

Member category

External Proprietary Director linked to Grupo Plafin, S.A.U. and Grupo Corporativo Landon, S.L.

Date of first appointment, and subsequent appointments

First appointment on 25/07/2014 by co-option; re-elected on 07/11/2014, on 08/05/2019, on 07/05/2021 and on 05/05/2023.

Company shares, and share options

Direct holder of 185 shares and indirect holder, together with other family members through the company Grupo Plafin, S.A., of 93,169,300 company shares, and indirect holder, together with other family members through Grupo Corporativo Landon, S.L., of 32,766,155 company shares.